1358P Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor

Authors
Category Primary study
JournalAnnals of Oncology
Year 2021
This article has no abstract
Epistemonikos ID: d6eabf40b38cb212dff27263694902d4109916d8
First added on: Feb 13, 2025